Literature DB >> 22718155

Probiotics for the prevention and treatment of Clostridium difficile in older patients.

Jasmin Islam1, Jonathan Cohen, Chakravarthi Rajkumar, Martin J Llewelyn.   

Abstract

Clostridium difficile infection (CDI) is the leading cause of nosocomial diarrhoea in older people, causing substantial morbidity and mortality. The fact that CDI is almost exclusively a disease of older people and the debilitated indicates that patient susceptibility is a major determinant of who gets CDI. It would help efforts to combat this disease if we better understood and could reduce patient susceptibility. In this regard, several strategies are currently under investigation. The use of probiotics for CDI has received particular attention in the medical and lay media. Patients and their carers often ask doctors about them. In this review article, we describe the pathogenesis of CDI before looking at the ageing host in more detail. We discuss how probiotics may work and review the current evidence for their use in CDI.

Entities:  

Mesh:

Year:  2012        PMID: 22718155     DOI: 10.1093/ageing/afs077

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  4 in total

Review 1.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  National age group trends in Clostridium difficile infection incidence and health outcomes in United States Community Hospitals.

Authors:  Ashley Pechal; Kevin Lin; Stefan Allen; Kelly Reveles
Journal:  BMC Infect Dis       Date:  2016-11-17       Impact factor: 3.090

Review 3.  Clostridium difficile infection in the elderly: an update on management.

Authors:  Tomefa E Asempa; David P Nicolau
Journal:  Clin Interv Aging       Date:  2017-10-24       Impact factor: 4.458

4.  Cost-benefit relation of diet and probiotics in iatrogenic bowel irregularity (IBI).

Authors:  Eric Claassen
Journal:  Front Pharmacol       Date:  2014-02-17       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.